EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 198 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΕΟΥΣ February 10, 2019 A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... September 21, 2023 FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma November 13, 2025 Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 Load more HOT NEWS Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΝΕΥΜΟΝΑ:ΝΕΑ ΜΕΛΕΤΗ, ΝΕΕΣ ΕΛΠΙΔΕΣ ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A...
